latest news releases from the newsroom
MorphoSys Announces Clinical Milestone in Partnered -- Third HuCAL-Based Antibody to Begin Clinical Trials
MARTINSRIED, Germany, June 21, 2007 (PRIME NEWSWIRE) -- MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment) announced today that an undisclosed partner has filed all necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody in the therapeutic area of oncology. This achievement marks the third fully human antibody developed with MorphoSys's core technology within its partnerships to enter human clinical trials and triggers a clinical milestone payment to MorphoSys.
Oakley to Merge Into Luxottica Group for US$29.30 Per Share
MILAN, Italy and FOOTHILL RANCH, Calif., June 20, 2007 (PRIME NEWSWIRE) -- Luxottica Group S.p.A. (NYSE:LUX) (MTA:LUX), global leader in eyewear, and Oakley, Inc. (NYSE:OO), worldwide specialist in sport performance optics, today jointly announced that they have entered into a definitive merger agreement with the unanimous approval of both companies' Boards of Directors. Under the agreement, Luxottica Group will acquire all of the outstanding shares of Oakley for a cash purchase price of US$29.30 per share, together with the purchase of all outstanding options and other equity rights at the same price per share less the exercise price. The total purchase price will be approximately US$2.1 billion, representing an approximate premium of 18% over the most recent 30-day average NYSE trading price of Oakley shares and approximately 24% over the most recent three-month average trading price.
Riverview Bancorp, Inc.
Riverview Bancorp Declares $0.11 Cash Dividend
VANCOUVER, Wash., June 20, 2007 (PRIME NEWSWIRE) -- Riverview Bancorp (Nasdaq:RVSB) today announced that its Board of Directors declared a quarterly cash dividend of $0.11 per share. Including the 2-for-1 stock split issued in August 2006, the cash payout to shareholders is up 16% from a year ago. The dividend will be paid on July 16, 2007, to shareholders of record June 29, 2007.
Izard Nobel LLP
Schatz Nobel Izard P.C. Announces Class Action Lawsuit Against Neurocrine Biosciences, Inc.
HARTFORD, Conn., June 20, 2007 (PRIME NEWSWIRE) -- The law firm of Schatz Nobel Izard P.C., which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the Southern District of California on behalf of all persons who purchased the common stock of Neurocrine Biosciences, Inc. ("Neurocrine") (Nasdaq:NBIX) between June 20, 2002 and June 23, 2006, inclusive (the "Class Period"). Also included are those who purchased in a Secondary Offering on September 11, 2003.